Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid

@article{Philpott2004InductionOT,
  title={Induction of tumour necrosis factor-$\alpha$ by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid},
  author={M. Philpott and B. Baguley and L. Ching},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={36},
  pages={143-148}
}
Abstract5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a low-molecular-weight biological response modifier scheduled for clinical evaluation, induced synthesis of tumour necrosis factor-α (TNF-α) in serum of mice, with maximal activity being observed at 2–3 h after administration. At a dose of 27.5 mg/kg, DMXAA induced similar TNF-α concentrations as did flavone-8-acetic acid given at its maximum tolerated dose (MTD; 330 mg/kg), whereas 8-methylxanthenone-4-acetic acid, which has no antitumour… Expand
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
TLDR
The results suggest an important role for tumour necrosis factor in mediating both the host toxicity and antitumour activity of 5,6-dimethylxanthenone-4-acetic acid, but also suggest that tumour Necrosis factor can be replaced by other vasoactive factors in its antitumours action, an observation of relevance to current clinical studies. Expand
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours
TLDR
This study shows for the first time that DMXAA has significant in vivo antitumour activity against non-transplanted autochthonous tumours and in a host species other than the mouse. Expand
Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.
TLDR
The results indicate that DMXAA rather than a metabolite is responsible for cytokine induction and suggest that the microenvironment of the tumour may be responsible for the observed selective induction of cytokines in tumour tissue. Expand
Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
TLDR
The use of a pharmacokinetically guided schedule provides excellent oral activity against Colon 38 tumors and provides a basis for developing more effective administration schedules in clinical trials. Expand
Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs
TLDR
NSAIDs increase the antitumour activity of DMXAA in a murine tumour model, consistent with hypothesis that NSAIDs antagonises some of the protective effects of prostaglandins released in response to vascular injury. Expand
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
TLDR
DMXAA was well tolerated at lower doses and no drug-related myelosuppression was seen, and Rapidly reversible dose-limiting toxicities were observed at 4900 mg m−2, including confusion, tremor, slurred speech, visual disturbance, anxiety, urinary incontinence and possible left ventricular failure. Expand
5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA): a New Biological Response Modifier for Cancer Therapy
TLDR
Co-administration of DMXAA with other drugs has been shown to result in enhanced anti-tumour activity andalterations in pharmacokinetics, asreported for the combination of DMxAA withmelphalan, thalidomide, cyproheptadine, and the bioreductive agent tirapazamine, inmouse models. Expand
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
TLDR
DMXAA is a novel vascular targeting agent and is well tolerated; dose-limiting toxicities in the form of urinary incontinence, visual disturbance, and anxiety were observed at the highest dose level. Expand
Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
TLDR
It is concluded that 5,6-Dimethylxanthenone-4-acetic acid can induce vascular endothelial cell apoptosis in some murine and human tumours and appears to be independent of tumour necrosis factor induction. Expand
Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.
TLDR
Data indicate that the transport of DMXAA across Caco-2 monolayers was through a passive process, whereas the transportofDMXAA-G was mediated by MRP1/2. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours
TLDR
No correlation is evident between cure rates, duration of growth delay, haemorrhagic necrosis and TNF-α induction by 5,6-MeXAA or LPS, and therapy using a combination of sub-optimal doses of both compounds was synergistic for the induction of serum T NF-α and message for TNF -α but was not synergism for antitumour efficacy. Expand
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
TLDR
The results suggest that 5,6-MeXAA would be a more active clinical agent than FAA because TNF-alpha induction appears to be a critical factor in the antitumor effects of this class of compounds. Expand
Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-methyl-xanthenone-4-acetic acid and flavone acetic acid
TLDR
The results are consistent with the hypothesis that the in vivo haematological effects of these compounds are indirect, perhaps being mediated through the induction of cytokines, and contrast with the haemorrhaging effects of conventional antitumour agents. Expand
Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid.
TLDR
The results suggest that 5,6-MeXAA acts on macrophages in a manner similar to that of endotoxin, utilizing a pathway which includes arachidonic acid metabolism and requiring cell-cell contact with target cells for a tumouricidal effect. Expand
Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice
TLDR
5,6-MeXAA bound to plasma proteins in a manner similar to that exhibited by FAA, although the plasma concentration of free drug was lower for the former than for the latter, as a consequence, the calculated maximal free drug concentration for 5, 6-Me XAA in plasma was 23 times lower than that for FAA. Expand
Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives.
  • H. Futami, L. Eader, +4 authors B. Baguley
  • Medicine
  • Journal of immunotherapy : official journal of the Society for Biological Therapy
  • 1992
TLDR
Results suggest that at least some of the antitumor effects of these XAA derivatives are related to their ability to induce cytokines. Expand
Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid.
TLDR
NK cell activity was increased in both mouse strains, indicating a lack of major involvement of this lymphocyte population in FAA efficacy, and antitumour efficacy of FAA was reduced when the treatment was followed by injection of antitumour necrosis factor alpha (TNF alpha) antibodies. Expand
Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice.
TLDR
It is shown here that FAA and structurally related analogues increase plasma nitrite plus nitrate (NO2-/NO3-) levels in mice, suggesting that nitric oxide may contribute to tumor cell death by two mechanisms, alteration of blood flow contributing to tumor ischemia and direct tumor cell killing. Expand
Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.
TLDR
It is demonstrated that FAA and ril-2 is a useful approach for cancer treatment in that subtoxic doses of rIL-2 can be used and significant anti-tumor efficacy occurs even without accompanying adoptive immunotherapy. Expand
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.
TLDR
Results show that FAA alone can induce cytokine release from primed target cells and may be associated with the therapeutic effect and/or toxicity of the agent. Expand
...
1
2
3
4
...